000304587 001__ 304587
000304587 005__ 20250916115009.0
000304587 0247_ $$2doi$$a10.1038/s41598-025-18319-w
000304587 0247_ $$2pmid$$apmid:40940449
000304587 0247_ $$2pmc$$apmc:PMC12432113
000304587 037__ $$aDKFZ-2025-01910
000304587 041__ $$aEnglish
000304587 082__ $$a600
000304587 1001_ $$00000-0002-9356-7940$$aGrätz, Christian$$b0
000304587 245__ $$aExtracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer.
000304587 260__ $$a[London]$$bSpringer Nature$$c2025
000304587 3367_ $$2DRIVER$$aarticle
000304587 3367_ $$2DataCite$$aOutput Types/Journal article
000304587 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757942471_16521
000304587 3367_ $$2BibTeX$$aARTICLE
000304587 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304587 3367_ $$00$$2EndNote$$aJournal Article
000304587 520__ $$aAnaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could be achieved by measurement of extracellular vesicle (EV)-associated cell-free RNA in liquid biopsy samples. Recent studies have discovered the potential of the receptor tyrosine kinase inhibitor vandetanib for ATC treatment in vitro and in vivo. Given the rarity of ATC patients receiving off-label vandetanib treatment, acquiring patient samples for clinical studies is a prolonged process, and pre-clinical investigations are needed to elucidate the effects of vandetanib on ATC cells. Here, we present an in vitro study addressing holistic transcriptional and proteomic changes induced in the ATC cell line Cal62 by three doses of vandetanib and quantified by high-throughput methods. By comparing the transcriptional and proteomic data sets and applying dimensional reduction models such as sparse partial least-squares discriminant analysis, we refined a set of 21 biomarker candidates. Out of these, we report a final signature of eight transcriptional biomarkers, validated in cellular and cell-free RNA by RT-qPCR and verified for biological significance and discriminatory power by pathway over-representation analysis and partial least-squares regression. This transcriptional biomarker signature can distinguish vandetanib treatment from control in cell-free RNA isolated from Cal62 EVs and can be measured reliably, easily, and quickly using RT-qPCR. Our findings may serve as a basis for future clinical trials with liquid biopsy samples from ATC patients undergoing off-label vandetanib treatment.
000304587 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304587 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304587 650_7 $$2Other$$aAnaplastic thyroid cancer
000304587 650_7 $$2Other$$aBiomarker
000304587 650_7 $$2Other$$aDrug repurposing
000304587 650_7 $$2Other$$aExtracellular vesicles
000304587 650_7 $$2Other$$aLiquid biopsy
000304587 650_7 $$2Other$$aTranscriptomics
000304587 7001_ $$00009-0004-5892-8706$$aChangoer, Prashant$$b1
000304587 7001_ $$aChiang, Dapi Menglin$$b2
000304587 7001_ $$00000-0002-3882-0093$$aKersting, Johannes$$b3
000304587 7001_ $$00000-0001-6994-493X$$aJaeger, Martin$$b4
000304587 7001_ $$00000-0002-9603-0460$$aNetea-Maier, Romana$$b5
000304587 7001_ $$00009-0001-6333-5233$$aWudy, Susanne I$$b6
000304587 7001_ $$00000-0002-6131-7322$$aLudwig, Christina$$b7
000304587 7001_ $$00000-0002-0941-4168$$aList, Markus$$b8
000304587 7001_ $$0P:(DE-He78)699e44c28c434a7656363fd3a2448989$$aKirchner, Benedikt$$b9$$udkfz
000304587 7001_ $$00000-0002-9113-9643$$aReithmair, Marlene$$b10
000304587 7001_ $$00000-0002-3192-1019$$aPfaffl, Michael W$$b11
000304587 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-025-18319-w$$gVol. 15, no. 1, p. 32464$$n1$$p32464$$tScientific reports$$v15$$x2045-2322$$y2025
000304587 909CO $$ooai:inrepo02.dkfz.de:304587$$pVDB
000304587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)699e44c28c434a7656363fd3a2448989$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000304587 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304587 9141_ $$y2025
000304587 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-29T15:28:26Z
000304587 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-29T15:28:26Z
000304587 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-07-29T15:28:26Z
000304587 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000304587 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000304587 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000304587 980__ $$ajournal
000304587 980__ $$aVDB
000304587 980__ $$aI:(DE-He78)B062-20160331
000304587 980__ $$aUNRESTRICTED